BASF Builds New Chemical Catalysts Manufacturing Plant in Caojing, Shanghai
BASF is further strengthening its manufacturing footprint in Asia Pacific with a new, world-scale chemical catalysts production facility at the company’s existing site in the Shanghai Chemical Industry Park in Caojing, Shanghai, China.
The plant — BASF’s first process catalysts manufacturing facility in Asia Pacific — will produce base metal catalysts, custom catalysts, and adsorbents to meet growing Chinese and Asian market demand. These catalysts are used in the production of fatty alcohols, sulfuric acid and butanediol and for the removal of impurities from olefins.
Construction of the new plant begins this month, with the launch of manufacturing activities planned for the fourth quarter of 2016. Once operating at full capacity, the plant will create 75 new jobs in Shanghai.
“The plant we are building in Caojing will provide a strong regional manufacturing base for our business and greatly improved proximity to our customers in Asia Pacific, which is the fastest growing region for our base metal and custom catalysts solutions,” said Dr Detlef Ruff, BASF Senior Vice President, Process Catalysts & Technologies. “This plant will be highly automated and energy efficient, offering room for additional expansion as well as flexibility to adapt to new customer production requirements in the years to follow.”
“By 2020, BASF aims for local production of approximately 75% of the products we sell in Asia Pacific, in order to intensify our collaboration with and strengthen our supply position to customers in the region. To achieve this, together with our partners we are investing €10 billion from 2013 to 2020 to further develop our local production footprint in Asia Pacific. BASF’s investment in the Caojing, Shanghai, chemical catalysts plant represents another milestone in the company’s regional growth strategy,” said Dr Albert Heuser, President Functions Asia Pacific, President and Chairman Greater China, BASF.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance